The 11 currently reportable or Tier 1/actionable variants for NSCLC (ALK, EGFR, BRAF, KRAS, NTRK1, NTRK2, NTRK3, ROS, RET, MET and ERBB2) were verified and commercial control material was utilised to supplement the verification. This evidence concerns the gene RET and non-small cell lung carcinoma.